Join to View Full Profile
92 2nd StHackensack, NJ 07601
Phone+1 551-996-3925
Fax+1 551-996-0574
Dr. McCloskey is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
MedStar Health Georgetown UniversityFellowship, Hematology and Medical Oncology, 2011 - 2014- MedStar Health Georgetown University/Georgetown HospitalResidency, Internal Medicine, 2008 - 2011
Georgetown University School of MedicineClass of 2008
Certifications & Licensure
NJ State Medical License 2014 - 2027
DC State Medical License 2008 - 2026
VA State Medical License 2008 - 2016
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016-2017
Clinical Trials
- Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML Start of enrollment: 2009 Oct 01
- Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant Start of enrollment: 2019 Mar 08
- Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML Start of enrollment: 2018 Aug 15
Publications & Presentations
PubMed
- Decitabine-cedazuridine in patients with MDS and TP53 mutations.Samuel Urrutia, Koji Sasaki, Alex Bataller, Hagop Kantarjian, Guillermo Montalban-Bravo
Blood Advances. 2026-02-10 - 1 citationsV-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML.Vinod A Pullarkat, Mark Levis, James McCloskey, Gabriel N Mannis, Stephen A Strickland
Blood Neoplasia. 2025-11-01 - B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia.Ashley Varkey, Manpreet Bariana, Mark Batistick, John Church, Elena Cassella
Journal of Hematology & Oncology. 2025-10-24
Abstracts/Posters
- Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...James McCloskey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing...James McCloskey, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Phil...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Molecular Epidemiologic Associations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) within the United States2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Opinion: The Pandemic and the RNA Sequencing GapSeptember 1st, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
